



## Clinical trial results:

### A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

#### Summary

EudraCT number	2014-005000-19
Trial protocol	HU DE ES PL
Global end of trial date	07 June 2019

#### Results information

Result version number	v1 (current)
This version publication date	27 March 2020
First version publication date	27 March 2020

#### Trial information

##### Trial identification

Sponsor protocol code	CR106661
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02349061
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 Route 202, Raritan, United States, NJ 08869
Public contact	Clinical Registry group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 June 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 June 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE).

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety and tolerability were evaluated by vital signs, general physical examinations and skin evaluations, adverse events, concomitant medication review, pregnancy testing, administration reactions, chemistry and hematology laboratory tests, and antibodies to ustekinumab.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 October 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 12
Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Spain: 12
Country: Number of subjects enrolled	Hungary: 8
Country: Number of subjects enrolled	Mexico: 11
Country: Number of subjects enrolled	Poland: 19
Country: Number of subjects enrolled	Taiwan: 13
Country: Number of subjects enrolled	United States: 17
Worldwide total number of subjects	102
EEA total number of subjects	44

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	99
From 65 to 84 years	3
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

166 subjects were screened during the study, 102 were enrolled/randomized and treated.

### Period 1

Period 1 title	Main Study: PCP (Up to Week 24)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects received placebo matched to ustekinumab intravenously (IV) at Week 0 then followed by placebo subcutaneously (SC) at Week 8 and 16.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Subjects received placebo matched to ustekinumab IV at Week 0 followed by placebo SC at Week 8 and 16.

<b>Arm title</b>	Ustekinumab
------------------	-------------

Arm description:

Subjects received an initial body weight range based IV dose approximating 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by 90 milligram (mg) SC administered every 8 weeks (q8w) at Week 8 and 16.

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Subjects received 6 mg/kg of ustekinumab at Week 0 followed by ustekinumab 90 mg SC administered q8w at Week 8 and 16.

Number of subjects in period 1	Placebo	Ustekinumab
Started	42	60
Completed	33	56
Not completed	9	4
Consent withdrawn by subject	2	-
Physician decision	1	-
Adverse event, non-fatal	4	3
Unspecified	1	1
Lack of efficacy	1	-

## Period 2

Period 2 title	Main Study: Week 24 to 56
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ustekinumab

### Arm description:

Subjects who were assigned to Ustekinumab treatment and who completed placebo controlled period (PCP) continued to receive ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up for 16 weeks after last study agent SC administration.

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

### Dosage and administration details:

Subjects received ustekinumab 90 mg SC administered q8w at Weeks 24, 32 and 40.

<b>Arm title</b>	Placebo to Ustekinumab
------------------	------------------------

### Arm description:

Subjects who received placebo matched to ustekinumab and completed PCP period in placebo group were crossed-over at Week 24 and received ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up through Week 56 in a blinded fashion for 16 weeks after last study agent SC administration.

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

### Dosage and administration details:

Subjects received ustekinumab 90 mg SC administered q8w at Weeks 24, 32 and 40.

<b>Number of subjects in period 2</b>	Ustekinumab	Placebo to Ustekinumab
Started	56	33
Completed	53	30
Not completed	3	3
Consent withdrawn by subject	-	1
Physician decision	-	1
Adverse event, non-fatal	2	1
Lack of efficacy	1	-

### Period 3

Period 3 title	Study Extension (Week 56 to Week 120)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ustekinumab

#### Arm description:

Per the amended study design, open-label ustekinumab 90 mg q8w SC administration will continue to be provided through Week 104 (study extension) to eligible subjects followed by safety follow-up through Week 120.

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

#### Dosage and administration details:

Subjects received ustekinumab 90 mg SC administered q8w starting at Week 48 or at Week 56 through Week 104.

<b>Arm title</b>	Placebo to Ustekinumab
------------------	------------------------

#### Arm description:

Per the amended study design, open-label ustekinumab 90 mg q8w SC administration will continue to be provided through Week 104 (study extension) to eligible subjects followed by safety follow-up through Week 120.

Arm type	Experimental
Investigational medicinal product name	Ustekinumab
Investigational medicinal product code	
Other name	STELARA
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

---

**Dosage and administration details:**

Subjects received ustekinumab 90 mg SC administered q8w starting at Week 48 or at Week 56 through Week 104.

<b>Number of subjects in period 3<sup>[1]</sup></b>	Ustekinumab	Placebo to Ustekinumab
Started	29	17
Completed	24	14
Not completed	5	3
Consent withdrawn by subject	2	1
Physician decision	-	1
Adverse event, non-fatal	3	-
Lack of efficacy	-	1

---

**Notes:**

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Subjects who were eligible to continue in extension phase are included in this period.

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
Subjects received placebo matched to ustekinumab intravenously (IV) at Week 0 then followed by placebo subcutaneously (SC) at Week 8 and 16.	
Reporting group title	Ustekinumab
Reporting group description:	
Subjects received an initial body weight range based IV dose approximating 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by 90 milligram (mg) SC administered every 8 weeks (q8w) at Week 8 and 16.	

Reporting group values	Placebo	Ustekinumab	Total
Number of subjects	42	60	102
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	42	57	99
From 65 to 84 years	0	3	3
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	43.1	40	
standard deviation	± 11.03	± 11.95	-
Title for Gender Units: subjects			
Female	35	58	93
Male	7	2	9



## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Subjects received placebo matched to ustekinumab intravenously (IV) at Week 0 then followed by placebo subcutaneously (SC) at Week 8 and 16.	
Reporting group title	Ustekinumab
Reporting group description: Subjects received an initial body weight range based IV dose approximating 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by 90 milligram (mg) SC administered every 8 weeks (q8w) at Week 8 and 16.	
Reporting group title	Ustekinumab
Reporting group description: Subjects who were assigned to Ustekinumab treatment and who completed placebo controlled period (PCP) continued to receive ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up for 16 weeks after last study agent SC administration.	
Reporting group title	Placebo to Ustekinumab
Reporting group description: Subjects who received placebo matched to ustekinumab and completed PCP period in placebo group were crossed-over at Week 24 and received ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up through Week 56 in a blinded fashion for 16 weeks after last study agent SC administration.	
Reporting group title	Ustekinumab
Reporting group description: Per the amended study design, open-label ustekinumab 90 mg q8w SC administration will continue to be provided through Week 104 (study extension) to eligible subjects followed by safety follow-up through Week 120.	
Reporting group title	Placebo to Ustekinumab
Reporting group description: Per the amended study design, open-label ustekinumab 90 mg q8w SC administration will continue to be provided through Week 104 (study extension) to eligible subjects followed by safety follow-up through Week 120.	

### Primary: Percentage of Subjects with a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24

End point title	Percentage of Subjects with a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24
End point description: SRI-4: greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new domain scores in either British Isles Lupus Assessment Group (BILAG) A or B and no worsening (less than 10% increase) from baseline in Physician's Global Assessment of Disease Activity (PGA). CR; SRI-4 response in subjects who do not meet treatment failure criteria. SLEDAI-2K total score range = 0-105, higher score means increased disease activity. BILAG Index: assesses clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assess disease activity on a visual analogue scale range= 0-10 (very well-very poor). Full analysis set (FAS) included all randomized subjects who received at least 1 dose (partial or complete, IV or SC) of ustekinumab or placebo.	
End point type	Primary
End point timeframe: Week 24	

End point values	Placebo	Ustekinumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	60		
Units: Percentage of subjects				
number (not applicable)	33.3	61.7		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Ustekinumab
Number of subjects included in analysis	102
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0057
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	3.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.41
upper limit	7.63

## Secondary: Change from Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) Score at Week 24

End point title	Change from Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) Score at Week 24
End point description:	
<p>The SLEDAI-2K is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE patients in the previous 30 days. It is weighted according to the feature. Features are scored by the assessing physician if present within the last 30 days with more severe features having higher scores, and then simply added to determine the total SLEDAI 2K score, which ranges from 0 to 105, with higher scores representing increased disease activity. FAS included all the randomized subjects who received at least 1 dose (partial or complete, IV or SC) of ustekinumab or placebo. Here, 'N' (number of subjects analyzed) signifies those subjects who were evaluable for this endpoint.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	Ustekinumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	31	53		
Units: Units on a scale				
arithmetic mean (standard deviation)	-3.8 (± 5.39)	-4.4 (± 2.91)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Ustekinumab
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0929
Method	Mixed model repeated measures model
Parameter estimate	Least Squares (LS) Mean Difference
Point estimate	-1.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.94
upper limit	0.23

## Secondary: Change from Baseline in Physician's Global Assessment of Disease Activity (PGA) Score at Week 24

End point title	Change from Baseline in Physician's Global Assessment of Disease Activity (PGA) Score at Week 24
End point description:	
PGA was recorded on a visual analogue scale (VAS; 0.0 to 10.0 centimeter [cm]). The scale for the physician's assessment ranges for 'no lupus activity' (0.0) to 'extremely active lupus' (10.0). FAS included all the randomized subjects who received at least 1 dose (partial or complete, IV or SC) of ustekinumab or placebo. Here, 'N' (number of subjects analyzed) signifies those subjects who were evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24	

End point values	Placebo	Ustekinumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	55		
Units: Units on a scale				
arithmetic mean (standard deviation)	-1.93 (± 2.168)	-2.17 (± 1.915)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Placebo v Ustekinumab
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3944
Method	Mixed model repeated measures model
Parameter estimate	LS Means Difference
Point estimate	-0.383
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.271
upper limit	0.506

## Secondary: Percentage of Subjects with BILAG-based Combined Lupus Assessment (BICLA) Response at Week 24

End point title	Percentage of Subjects with BILAG-based Combined Lupus Assessment (BICLA) Response at Week 24
End point description: BICLA response defined as subjects meeting following criteria: 1. BILAG improvement (all BILAG A scores at baseline improved to either B, C or D and all BILAG B scores at baseline improved to C or D and no worsening in disease activity defined as no new BILAG A scores and ≤ 1 new BILAG B score) and 2. no worsening of total SLEDAI-2K from baseline 3. < 1 cm increase in PGA and 4. no treatment failure criteria met. BILAG: assesses disease extent, severity (range: A [severe] to E [no disease]). SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). PGA: assesses worsening in subject's general health status (0.0= 'no lupus activity' to 10.0 = 'extremely active lupus'). FAS included all the randomized subjects who received at least 1 dose (partial or complete, IV or SC) of ustekinumab or placebo.	
End point type	Secondary
End point timeframe: Week 24	

<b>End point values</b>	Placebo	Ustekinumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	60		
Units: Percentage of subjects				
number (not applicable)	33.3	35		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Placebo v Ustekinumab
Number of subjects included in analysis	102
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9939
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	2.34

## Secondary: Change from Baseline in Number of Joints with Pain and Signs of Inflammation at Week 24

End point title	Change from Baseline in Number of Joints with Pain and Signs of Inflammation at Week 24
End point description: Change from baseline in number of joints (active joint) with pain and signs of inflammation (tenderness, swelling or effusion) for subjects with at least 2 affected joints at baseline were reported. An active joint is defined as a joint with pain and signs of inflammation (e.g., tenderness, swelling or effusion). FAS included all the randomized subjects who received at least 1 dose (partial or complete, IV or SC) of ustekinumab or placebo. Population included subjects with at least 2 affected joints at baseline (2 or more affected joints).	
End point type	Secondary
End point timeframe: Baseline, Week 24	

<b>End point values</b>	Placebo	Ustekinumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	31	51		
Units: Joints				
arithmetic mean (standard deviation)	-2.8 (± 7.31)	-4.5 (± 4.42)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Placebo v Ustekinumab
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1032
Method	Mixed model repeated measures model
Parameter estimate	LS Means Difference
Point estimate	-2.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.78
upper limit	0.45

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Screening up to Week 120

Adverse event reporting additional description:

Safety analysis set was defined as the set of all randomized subjects who have received at least 1 dose (partial or complete, intravenously [IV] or subcutaneously [SC]) of ustekinumab or placebo.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

### Reporting groups

Reporting group title	Placebo (Up to Week 24)
-----------------------	-------------------------

Reporting group description:

Subjects received placebo matched to ustekinumab intravenously (IV) at Week 0 then followed by placebo subcutaneously (SC) at Week 8 and 16.

Reporting group title	Ustekinumab (Up to Week 24)
-----------------------	-----------------------------

Reporting group description:

Subjects received an initial body weight range based IV dose approximating 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by 90 mg SC administered every 8 weeks (q8w) at Week 8 and 16.

Reporting group title	Placebo to Ustekinumab (Week 24 to 56)
-----------------------	--

Reporting group description:

Subjects who received placebo matched to ustekinumab and completed PCP period in placebo group were crossed-over at Week 24 and received ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up through Week 56 in a blinded fashion for 16 weeks after last study agent SC administration.

Reporting group title	Ustekinumab (Week 24 to 56)
-----------------------	-----------------------------

Reporting group description:

Subjects who were assigned to Ustekinumab treatment and who completed placebo controlled period (PCP) continued to receive ustekinumab 90 mg SC at Weeks 24, 32, and 40 followed by safety follow-up for 16 weeks after last study agent SC administration.

Reporting group title	Placebo to Ustekinumab (Week 56 to 120)
-----------------------	---

Reporting group description:

Per the amended study design, open-label ustekinumab 90 mg q8w SC administration will continue to be provided through Week 104 (study extension) to eligible subjects followed by safety follow-up through Week 120.

Reporting group title	Ustekinumab (Week 56 to 120)
-----------------------	------------------------------

Reporting group description:

Per the amended study design, open-label ustekinumab 90 mg q8w SC administration will continue to be provided through Week 104 (study extension) to eligible subjects followed by safety follow-up through Week 120.

Serious adverse events	Placebo (Up to Week 24)	Ustekinumab (Up to Week 24)	Placebo to Ustekinumab (Week 24 to 56)
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 42 (9.52%)	5 / 60 (8.33%)	5 / 33 (15.15%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Keratoacanthoma			
subjects affected / exposed	1 / 42 (2.38%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Humerus Fracture			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Raynaud's Phenomenon			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary Artery Occlusion			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic Stroke			
subjects affected / exposed	0 / 42 (0.00%)	1 / 60 (1.67%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Posterior Reversible Encephalopathy Syndrome			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			



Hypochromic Anaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic Reaction			
subjects affected / exposed	0 / 42 (0.00%)	1 / 60 (1.67%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastric Ulcer			
subjects affected / exposed	1 / 42 (2.38%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis Acute			
subjects affected / exposed	0 / 42 (0.00%)	1 / 60 (1.67%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	1 / 42 (2.38%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus Nephritis			

subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Systemic Lupus Erythematosus			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Bacteraemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 60 (1.67%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic Sepsis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 60 (1.67%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella Sepsis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Sinusitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas Infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral Infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Ustekinumab (Week 24 to 56)	Placebo to Ustekinumab (Week 56 to 120)	Ustekinumab (Week 56 to 120)
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 56 (12.50%)	1 / 17 (5.88%)	4 / 29 (13.79%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Keratoacanthoma			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Humerus Fracture			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			

subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Raynaud's Phenomenon			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary Artery Occlusion			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic Stroke			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Posterior Reversible Encephalopathy Syndrome			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Hypochromic Anaemia			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic Reaction			

subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastric Ulcer			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis Acute			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus Nephritis			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Systemic Lupus Erythematosus			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			

subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic Sepsis			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 56 (0.00%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella Sepsis			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 56 (0.00%)	1 / 17 (5.88%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas Infection			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			

subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Viral Infection</b>			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo (Up to Week 24)	Ustekinumab (Up to Week 24)	Placebo to Ustekinumab (Week 24 to 56)
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	25 / 42 (59.52%)	30 / 60 (50.00%)	21 / 33 (63.64%)
<b>Vascular disorders</b>			
Peripheral Arterial Occlusive Disease			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences (all)	0	0	1
<b>General disorders and administration site conditions</b>			
Pyrexia			
subjects affected / exposed	0 / 42 (0.00%)	3 / 60 (5.00%)	0 / 33 (0.00%)
occurrences (all)	0	3	0
Fatigue			
subjects affected / exposed	0 / 42 (0.00%)	2 / 60 (3.33%)	2 / 33 (6.06%)
occurrences (all)	0	2	3
<b>Reproductive system and breast disorders</b>			
Menstruation Irregular			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences (all)	0	0	1
Ovarian Cyst			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	2 / 33 (6.06%)
occurrences (all)	0	0	2
<b>Investigations</b>			
Alanine Aminotransferase Increased			

subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	1 / 60 (1.67%) 1	1 / 33 (3.03%) 3
Aspartate Aminotransferase Increased subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	2 / 60 (3.33%) 3	1 / 33 (3.03%) 4
Injury, poisoning and procedural complications Limb Injury subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 60 (0.00%) 0	1 / 33 (3.03%) 1
Nervous system disorders Headache subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 5	4 / 60 (6.67%) 4	1 / 33 (3.03%) 1
Blood and lymphatic system disorders Leukopenia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 4	0 / 60 (0.00%) 0	2 / 33 (6.06%) 4
Neutropenia subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 3	1 / 60 (1.67%) 1	2 / 33 (6.06%) 4
Anaemia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 60 (0.00%) 0	2 / 33 (6.06%) 2
Eye disorders Dry Eye subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 60 (0.00%) 0	2 / 33 (6.06%) 2
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	4 / 60 (6.67%) 5	3 / 33 (9.09%) 3
Nausea subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3	3 / 60 (5.00%) 3	1 / 33 (3.03%) 1
Hepatobiliary disorders			



Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 60 (0.00%) 0	1 / 33 (3.03%) 1
Skin and subcutaneous tissue disorders			
Actinic Keratosis subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2	0 / 60 (0.00%) 0	1 / 33 (3.03%) 1
Skin Lesion subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 60 (0.00%) 0	1 / 33 (3.03%) 1
Renal and urinary disorders			
Proteinuria subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 60 (0.00%) 0	0 / 33 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	0 / 60 (0.00%) 0	0 / 33 (0.00%) 0
Back Pain subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	2 / 60 (3.33%) 2	0 / 33 (0.00%) 0
Systemic Lupus Erythematosus subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	3 / 60 (5.00%) 3	2 / 33 (6.06%) 3
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	2 / 60 (3.33%) 2	1 / 33 (3.03%) 1
Gastroenteritis subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	1 / 60 (1.67%) 1	3 / 33 (9.09%) 3
Gastroenteritis Viral subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	0 / 60 (0.00%) 0	0 / 33 (0.00%) 0
Nasopharyngitis			

subjects affected / exposed	3 / 42 (7.14%)	6 / 60 (10.00%)	2 / 33 (6.06%)
occurrences (all)	3	7	4
Pharyngitis			
subjects affected / exposed	0 / 42 (0.00%)	3 / 60 (5.00%)	1 / 33 (3.03%)
occurrences (all)	0	3	1
Pharyngotonsillitis			
subjects affected / exposed	0 / 42 (0.00%)	3 / 60 (5.00%)	0 / 33 (0.00%)
occurrences (all)	0	3	0
Tooth Abscess			
subjects affected / exposed	0 / 42 (0.00%)	1 / 60 (1.67%)	1 / 33 (3.03%)
occurrences (all)	0	1	1
Upper Respiratory Tract Infection			
subjects affected / exposed	9 / 42 (21.43%)	5 / 60 (8.33%)	3 / 33 (9.09%)
occurrences (all)	9	6	4
Urinary Tract Infection			
subjects affected / exposed	4 / 42 (9.52%)	6 / 60 (10.00%)	6 / 33 (18.18%)
occurrences (all)	4	6	10
Infected Bite			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences (all)	0	0	1
Respiratory Tract Infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Tinea Versicolour			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences (all)	0	0	1
Tooth Infection			
subjects affected / exposed	0 / 42 (0.00%)	1 / 60 (1.67%)	2 / 33 (6.06%)
occurrences (all)	0	1	2
Vulvitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Diabetes Mellitus			
subjects affected / exposed	0 / 42 (0.00%)	0 / 60 (0.00%)	1 / 33 (3.03%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	Ustekinumab (Week 24 to 56)	Placebo to Ustekinumab (Week 56 to 120)	Ustekinumab (Week 56 to 120)
Total subjects affected by non-serious adverse events subjects affected / exposed	34 / 56 (60.71%)	8 / 17 (47.06%)	22 / 29 (75.86%)
Vascular disorders Peripheral Arterial Occlusive Disease subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	1 / 17 (5.88%) 1	0 / 29 (0.00%) 0
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 2  1 / 56 (1.79%) 1	0 / 17 (0.00%) 0  0 / 17 (0.00%) 0	1 / 29 (3.45%) 1  0 / 29 (0.00%) 0
Reproductive system and breast disorders Menstruation Irregular subjects affected / exposed occurrences (all)  Ovarian Cyst subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0  1 / 56 (1.79%) 1	1 / 17 (5.88%) 1  0 / 17 (0.00%) 0	0 / 29 (0.00%) 0  1 / 29 (3.45%) 1
Investigations Alanine Aminotransferase Increased subjects affected / exposed occurrences (all)  Aspartate Aminotransferase Increased subjects affected / exposed occurrences (all)	2 / 56 (3.57%) 2  1 / 56 (1.79%) 1	1 / 17 (5.88%) 2  1 / 17 (5.88%) 2	1 / 29 (3.45%) 1  1 / 29 (3.45%) 1
Injury, poisoning and procedural complications Limb Injury subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	1 / 17 (5.88%) 1	0 / 29 (0.00%) 0
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	3 / 56 (5.36%) 3	0 / 17 (0.00%) 0	2 / 29 (6.90%) 2
Blood and lymphatic system disorders			
Leukopenia subjects affected / exposed occurrences (all)	4 / 56 (7.14%) 10	1 / 17 (5.88%) 1	4 / 29 (13.79%) 7
Neutropenia subjects affected / exposed occurrences (all)	3 / 56 (5.36%) 8	1 / 17 (5.88%) 1	3 / 29 (10.34%) 6
Anaemia subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1	0 / 17 (0.00%) 0	1 / 29 (3.45%) 1
Eye disorders			
Dry Eye subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1	0 / 17 (0.00%) 0	1 / 29 (3.45%) 1
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	3 / 56 (5.36%) 3	0 / 17 (0.00%) 0	0 / 29 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1	0 / 17 (0.00%) 0	0 / 29 (0.00%) 0
Hepatobiliary disorders			
Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	1 / 17 (5.88%) 1	0 / 29 (0.00%) 0
Skin and subcutaneous tissue disorders			
Actinic Keratosis subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	1 / 17 (5.88%) 1	0 / 29 (0.00%) 0
Skin Lesion subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 2	1 / 17 (5.88%) 1	1 / 29 (3.45%) 2
Renal and urinary disorders			

Proteinuria subjects affected / exposed occurrences (all)	2 / 56 (3.57%) 2	0 / 17 (0.00%) 0	2 / 29 (6.90%) 2
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 17 (0.00%) 0	0 / 29 (0.00%) 0
Back Pain subjects affected / exposed occurrences (all)	5 / 56 (8.93%) 6	0 / 17 (0.00%) 0	1 / 29 (3.45%) 1
Systemic Lupus Erythematosus subjects affected / exposed occurrences (all)	2 / 56 (3.57%) 2	1 / 17 (5.88%) 2	2 / 29 (6.90%) 2
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	4 / 56 (7.14%) 4	0 / 17 (0.00%) 0	4 / 29 (13.79%) 4
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	2 / 17 (11.76%) 2	0 / 29 (0.00%) 0
Gastroenteritis Viral subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 17 (0.00%) 0	0 / 29 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	6 / 56 (10.71%) 7	1 / 17 (5.88%) 2	2 / 29 (6.90%) 3
Pharyngitis subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 2	0 / 17 (0.00%) 0	1 / 29 (3.45%) 1
Pharyngotonsillitis subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 17 (0.00%) 0	0 / 29 (0.00%) 0
Tooth Abscess subjects affected / exposed occurrences (all)	3 / 56 (5.36%) 3	0 / 17 (0.00%) 0	3 / 29 (10.34%) 3
Upper Respiratory Tract Infection			

subjects affected / exposed	10 / 56 (17.86%)	1 / 17 (5.88%)	3 / 29 (10.34%)
occurrences (all)	17	1	6
Urinary Tract Infection			
subjects affected / exposed	10 / 56 (17.86%)	2 / 17 (11.76%)	6 / 29 (20.69%)
occurrences (all)	17	3	7
Infected Bite			
subjects affected / exposed	0 / 56 (0.00%)	1 / 17 (5.88%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Respiratory Tract Infection			
subjects affected / exposed	2 / 56 (3.57%)	0 / 17 (0.00%)	2 / 29 (6.90%)
occurrences (all)	2	0	2
Tinea Versicolour			
subjects affected / exposed	0 / 56 (0.00%)	1 / 17 (5.88%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Tooth Infection			
subjects affected / exposed	1 / 56 (1.79%)	0 / 17 (0.00%)	1 / 29 (3.45%)
occurrences (all)	1	0	1
Vulvitis			
subjects affected / exposed	0 / 56 (0.00%)	1 / 17 (5.88%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Diabetes Mellitus			
subjects affected / exposed	0 / 56 (0.00%)	1 / 17 (5.88%)	0 / 29 (0.00%)
occurrences (all)	0	1	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 May 2015	Overall reason for this amendment was to clarify the use of highly effective methods of contraception for subject inclusion and continuation in the study, and correction of minor errors and omissions.
24 November 2015	Overall reasons for this amendment was to provide clarification regarding 1) subject eligibility and enrollment, 2) use of restricted and prohibited concomitant medications, 3) refine the definition of primary endpoint, 4) specify conditions under which subjects may undergo retesting at screening, 5) elaborate on statistical procedures to be used to conduct interim and planned data analyses, and 6) provide additional information regarding collection of samples.
18 January 2017	Overall reason for this amendment was to further evaluate the safety and efficacy of long-term ustekinumab administration in subjects with Systemic Lupus Erythematosus (SLE) who participated in CNT01275SLE2001 study extension.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported